Targets › SHANK3
2 programs from 2 companies in 2 trials: 2 Phase 1; Other; next expected readout May 2027.
Major scaffold postsynaptic density protein which interacts with multiple proteins and complexes to orchestrate the dendritic spine and synapse formation, maturation and maintenance. Interconnects receptors of the postsynaptic membrane including NMDA-type and metabotropic glutamate receptors via complexes with GKAP/PSD-95 and HOMER, respectively, and the actin-based cytoskeleton. (UniProt, Q9BYB0)
Open in Phaseline: the race on SHANK3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peking University First Hospital | RB001 Gene therapy targeting SHANK3 deficiency | SHANK3 | Phase 1 | Phelan-McDermid Syndrome | May 2027 |
| Jaguar Gene Therapy | JAG201 Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9 | SHANK3 | Phase 1 | SHANK3 Haploinsufficiency | Jun 2028 |
SHANK3 Haploinsufficiency (1) Phelan-McDermid Syndrome (1)
other (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.